α-Eleostearic Acid as a Senolytic Therapy - Quick Reference Sheet

α-Eleostearic Acid as a Senolytic Therapy

Created on 07/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A natural fatty acid from bitter melon and tung seed oils, studied as a way to clear worn-out "zombie" cells thought to drive aging. In lab and mouse studies it selectively killed these cells and improved some health measures. No human testing exists, so safe dose, benefit, and side effects remain unknown. (Full Review)

Protocol

Dose
None established
No human dose exists; only mouse regimens (50 mg/kg for 5 consecutive days, or oral dosing 3× weekly)
Form
Methyl ester (α-ESA-me)
Methyl ester outperformed the free acid in vivo; more stable and longer-acting
Pattern
Intermittent "hit-and-run"
Mouse studies used short courses and intermittent weekly dosing; continuous low-dose is the untested alternative
Time to effect
Humans
Unknown
No human timeframe defined; senolytic benefits are inherently hard to perceive subjectively
Aged mice
Within days
Senescence markers fell within days of a short (5-day) dosing course
Progeroid mice
~6 weeks
Composite aging-symptom score improved over six weeks of thrice-weekly dosing; effect diminished by week 16

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Iron-overload disorders (hereditary hemochromatosis, transfusion-dependent conditions)
  • G6PD deficiency
  • Advanced kidney or liver disease
  • Children
  • Inability to obtain a purity-verified product
Key Interactions
  • Antioxidant supplements (vitamin E, high-dose vitamin C, N-acetylcysteine)
  • Iron supplements and iron-raising conditions
  • Glucose-lowering drugs (insulin, sulfonylureas)
  • Anticoagulants and antiplatelet agents (warfarin, aspirin)
  • Other ferroptosis inducers or PPAR-γ agonists (pioglitazone)
  • Selenium status

Risk & Side Effects

  • High: Absence of any human safety data at senolytic doses
  • Medium: Adverse effects from the dietary source; off-target ferroptosis
  • Low: Pro-oxidant and lipid-peroxidation burden; metabolic conversion to conjugated linoleic acid with its own effects
  • Speculative: Impaired tissue repair from clearing beneficial senescent cells; reproductive and developmental risk

Monitoring

Marker Target Why
Ferritin 30–150 ng/mL (avoid high end) Iron fuels ferroptosis; high stores raise off-target risk
Transferrin saturation 20–35% Reflects available circulating iron for ferroptosis
Fasting glucose 70–90 mg/dL Source material lowers glucose; detects hypoglycemia risk
HbA1c 4.8–5.4% Longer-term glucose context if using glucose-lowering seed oils
eGFR / creatinine eGFR >90 mL/min/1.73m² Ferroptosis is implicated in kidney injury; monitors off-target organ effect
ALT / AST ALT <25 (men), <20 (women) U/L Liver is iron-rich and ferroptosis-susceptible; screens for hepatic stress
Selenium 110–150 μg/L Required cofactor for GPX4, the main ferroptosis defense
hs-CRP <1.0 mg/L Tracks systemic inflammation that senescent cells drive

Cadence: Baseline, ~1–2 weeks after an initial course, then every 3–6 months if repeated cycles are pursued (inferred, not evidence-based)

Qualitative Assessment

  • Energy and vitality
  • Cognitive clarity
  • Physical function (grip strength, mobility, recovery)
  • General tolerability